Myovant Sciences is focused on innovative treatments for women's health conditions and prostate cancer. The company's lead program is relugolix, a phase 3 drug candidate for multiple indications, including uterine fibroids, endometriosis and prostate cancer. Myovant was formed through a strategic partnership between Roivant Sciences and Takeda.
CEO: Lynn Seely
CFO: Frank Karbe
Please click here for Myovant Sciences job opportunities.
Please click here for clinical trial information.